Abstract
Fibroblast growth factor 8 (FGF8) has been shown to play a key role in prostate carcinogenesis. It was initially cloned as an androgen induced protein in mouse mammary cancer SC3 cells. In this study, we examined if FGF8 was also regulated by the androgen receptor in human prostate cancer. FGF8b protein expression in resected clinical prostate cancer correlated closely with expression of the androgen receptor (AR). In the androgen sensitive CWR22 prostate xenograft, we observed up-regulation of FGF8b immunoreactivity in testosterone supplemented mice while castration markedly reduced its signal. Furthermore, FGF8b protein expression in AR positive LNCaP cells was similarly enhanced by androgens. The proximal promoter of the human FGF8 gene was cloned into a luciferase reporter construct (FGF8.luc). FGF8.luc activity in AR positive LNCaP and SC3 cells was increased 2.5-fold by androgens. In AR negative DU145 cells, maximal induction of FGF8.luc required both co-transfection of the AR and the presence of androgens. The anti-androgen bicalutamide completely abolished AR mediated FGF8.luc induction. Deletion constructs from FGF8.luc have further defined an active promoter region and an androgen responsive region. Nucleotide analysis of this androgen responsive region has revealed putative androgen response elements. Finally, using ChIP assays we confirmed in vivo interaction between the AR and the androgen responsive region of the FGF8 promoter. Taken together these data provide first evidence that expression of the mitogen FGF8 in prostate cancer is, at least in part, regulated by the androgen receptor at the transcriptional level.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- AR:
-
androgen receptor
- ARE:
-
androgen response element
- FGF8:
-
fibroblast growth factor 8
- ChIP:
-
chromatin immunoprecipitation
- CWR22:
-
Case Western Reserve Prostate Xenograft strain 22
- MMTV:
-
mouse mammary tumour virus
- PCR:
-
polymerase chain reaction
- PSA:
-
prostate specific antigen
- SHR:
-
steroid hormone receptor
References
Bower M, Waxman J . 1997 Sem. Cancer Biol. 8: 3–9
Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN . 1999 J. Biol. Chem. 274: 17599–17604
Claessens F, Verrijdt G, Schoenmaker E, Haelens A, Peeters B, Verhoven G, Rombauts W . 2001 J. Steroid Biochem. Mol. Biol. 76: 23–30
Crossley PH, Minowada G, MacArthur CA, Martin GR . 1996 Cell 84: 127–136
Daphna-Iken D, Shankar DB, Lawshwe A, Ornitz DM, Shackleford GM, MacArthur CA . 1998 Oncogene 17: 2711–2717
De Vere White RW, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH . 1997 Eur. Urol. 31: 1–6
Dorkin TJ, Robinson MR, Marsh C, Bjartell A, Neal DE, Leung HY . 1999 Oncogene 18: 2755–2761
Gemel J, Gorry M, Ehrlich GD, MacArthur CA . 1996 Genomics 35: 253–257
Gemel J, Jacobsen C, MacArthur C . 1999 J. Biol. Chem. 274: 6020–6026
Ghosh AK, Shankar DB, Shakleford GM, Wu K, T'Ang A, Miller GJ, Zheng J, Roy-Burman P . 1996 Cell Growth Diff. 7: 1425–1434
Glass CK, Rose DW, Rosenfeld MG . 1997 Curr. Opin. Cell. Biol. 9: 222–232
Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN . 2001 Br. J. Cancer 85: 1928–1936
Greenlee RT, Murray T, Bolden S, Wingo PA . 2000 Can. J. Clin. 50: 7–33
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung LS . 1996 Mol. Endocrinology 10: 1167–1177
Ittman M, Mansukhani A . 1997 J. Urol. 157: 351–356
Kapoun AM, Shackleford GM . 1997 Oncogene 14: 2985–2989
Koivisto PA, Helin HJ . 1999 J. Pathol. 189: 219–223
Kouhara H, Koga M, Kasayama S, Tanaka A, Kishimoto T, Sato B . 1994 Oncogene 9: 455–462
Kuriki K, Kamiakito T, Yoshida H, Saito K, Fukayama M, Tanaka A . 2000 Cell Mol. Biol. 46: 1147–1156
Lee SM, Danielian PS, Fritzsch B, McMahon AP . 1997 Development 124: 959–969
Leung HY, Dickson C, Robson CN, Neal DE . 1996 Oncogene 12: 1833–1835
MacArthur CA, Lawshe A, Shankar DB, Heikinheimo M, Shackleford GM . 1995 Cell Growth Diff. 6: 817–825
Merril RM, Potosky AL, Feuer EJ . 1996 J. Natl. Can. Inst. 88: 1683–1685
Myers RB, Oeschlager DK, Coan PN, Frost AR, Weiss HL, Manne U, Pretlow TG, Grizzle WE . 1999 J. Urol. 161: 945–949
Murtha P, Tindall DJ, Young CY . 1993 Biochemistry 32: 6459–6464
Riegman PH, Vlietstra RJ, van der Korput J, Brinkmann AO, Trapman J . 1991 Mol. Endocrinology 5: 1921–1930
Roche PJ, Hoare S, Parker MG . 1992 Mol. Endocrinology 6: 2229–2235
Rudra-Ganguly N, Zheng J, Hoang AT, Roy-Burman P . 1998 Oncogene 16: 1487–1492
Schmitt FJ, Hearn MT, Risbridger GP . 1996 J. Steroid Biochem. Mol. Biol. 57: 173–178
Smith CL, Onate SA, Tsai MJ, McDonnel PD, O'Malley BW . 1996 Proc. Natl. Acad. Sci. USA 93: 8884–8888
Song Z, Powell W, Kasahara N, Van Bokhoven A, Miller G, Roy-Burman P . 2000 Cancer Res. 60: 6730–6736
Story MT, Hopp KA, Molter M, Meier DA . 1994 Growth Factors 10: 269–280
Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K . 1992 Proc. Natl. Acad. Sci. USA 89: 8928–8932
Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukuyama M . 1998 Cancer Res. 58: 2053–2056
Tanaka S, Ueo H, Mafune K, Mori M, Wands JR, Sugimachi K . 2001 Dig. Dis. and Sci. 46: 1016–1021
Valve EM, Tasanen MJ, Ruohola JK, Harkonen PL . 1998 Biochem. and Biophys. Res. Comm. 250: 805–808
Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Harkonen PL . 2001 Lab. Invest. 81: 815–826
Van der Kwast T, Schalken J, Ruizveld de Winter J, van Vroonhoven C, Mulder E, Boersma W, Trapman J . 1991 Int. J. Cancer 48: 189–193
Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TG, Bodner DR, Kursh ED . 1994 Cancer Res. 54: 6049–6052
Wang Q, Stamp GW, Powell S, Abel P, Laniado M, Mahony C, Lalani EN, Waxman J . 1999 J. Clin. Pathol. 52: 29–34
Wu J, Payson RA, Lang JC, Chiu IM . 1997 J. Steroid Biochem. Mol. Biol. 62: 1–10
Yeh S, Chang C . 1996 Proc. Natl. Acad. Sci. USA 93: 5517–5521
Yoshiura K, Leysens NJ, Chang J, Ward D, Murray JC, Muenke M . 1997 Am. J. Med. Gen. 72: 354–362
Acknowledgements
This project was funded by the Cancer Research Campaign of the UK, grant no SP2503/0101. We thank Dr Clive Dickson (Imperial Cancer Research Fund, London, UK) for the human FGF8 genomic clone, Professor TG Pretlow (Case Western Reserve University, Cleveland, Ohio, USA) for the CWR22 cells, Professor DR Newell (Cancer Research Unit, University of Newcastle-upon-Tyne) for assistance with the animal studies. We thank Susan Cook and Louise McCarthy for expert technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gnanapragasam, V., Robson, C., Neal, D. et al. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 21, 5069–5080 (2002). https://doi.org/10.1038/sj.onc.1205663
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205663
Keywords
This article is cited by
-
Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist
Journal of Nanobiotechnology (2023)
-
Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression
Scientific Reports (2017)
-
FGF8b oncogene mediates proliferation and invasion of Epstein–Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation
Oncogene (2011)
-
Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer
Laboratory Investigation (2008)
-
Identification of novel androgen receptor target genes in prostate cancer
Molecular Cancer (2007)